title: New perspectives in ovarian cancer treatment.
abstract: Ovarian cancer (OC) is increasingly understood as a heterogeneous disease comprising distinct subtypes of different origin that vary significantly with regard to molecular biology and clinical behaviour. Despite some limited progress in its treatment over the last decade, currently there are few therapeutic options and overall survival remains poor. Increasing knowledge about the molecular biology of ovarian cancer has led to the development of targeted therapies which promise to be more effective and to provide the basis for personalized treatment. The most successful strategies so far are employing anti-angiogenics (VEGF antibodies, tyrosine kinase inhibitors and angiopoietin antagonists) and polyadenosine diphosphate-ribose polymerase (PARP) inhibitors. Other approaches target aberrant OC signalling such as the PI3K/Akt/mTOR network, the epidermal growth factor receptor, the WEE1 tyrosine kinase and the folate receptor alpha. Immunotherapy is another promising new approach against ovarian cancer. In this area, immunotherapeutic modulation by administering autologous immune cells, such as dendritic cells (DCs), to stimulate antitumour host responses is of special interest. Finally, there is now growing evidence from clinical studies showing a survival advantage for intraperitoneal (IP) chemotherapy when compared to conventional intravenous treatment in the adjuvant setting. New strategies such as pressurized IP aerosol chemotherapy might further improve the efficacy of this approach.
authors.affiliation: Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, South Australia, Australia.
authors.forename: Bernd C
authors.initials: BC
authors.lastname: Schmid
authors.affiliation: Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, South Australia, Australia; Discipline of Obstetrics and Gynaecology, Research Centre for Reproductive Health, Robinson Institute, University of Adelaide, Adelaide 5005, South Australia, Australia. Electronic address: martin.oehler@adelaide.edu.au.
authors.forename: Martin K
authors.initials: MK
authors.lastname: Oehler
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007263:Infusions, Parenteral; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: Anti-angiogenic therapy; Immunotherapy; Intraperitoneal chemotherapy; Ovarian cancer; PARP inhibitors; Targeted therapy